{Reference Type}: Journal Article
{Title}: Dosimetric and NTCP analyses for selecting parotid gland cancer patients for proton therapy.
{Author}: Camarda AM;Vincini MG;Russo S;Comi S;Emiro F;Bazani A;Ingargiola R;Vischioni B;Vecchi C;Volpe S;Orecchia R;Jereczek-Fossa BA;Orlandi E;Alterio D;
{Journal}: Tumori
{Volume}: 110
{Issue}: 4
{Year}: 2024 Aug 21
{Factor}: 2.149
{DOI}: 10.1177/03008916241252544
{Abstract}: <B>UNASSIGNED: </B>To perform a dosimetric and a normal tissue complication probability (NTCP) comparison between intensity modulated proton therapy and photon volumetric modulated arc therapy in a cohort of patients with parotid gland cancers in a post-operative or radical setting.<BR><B>UNASSIGNED: </B>From May 2011 to September 2021, 37 parotid gland cancers patients treated at two institutions were eligible. Inclusion criteria were as follows: patients aged ⩾ 18 years, diagnosis of parotid gland cancers candidate for postoperative radiotherapy or definitive radiotherapy, presence of written informed consent for the use of anonymous data for research purposes. Organs at risk (OARs) were retrospectively contoured. Target coverage goal was defined as D95 > 98%. Six NTCP models were selected. NTCP profiles were calculated for each patient using an internally-developed Python script in RayStation TPS. Average differences in NTCP between photon and proton plans were tested for significance with a two-sided Wilcoxon signed-rank test.<BR><B>UNASSIGNED: </B>Seventy-four plans were generated. A lower Dmean to the majority of organs at risk (inner ear, cochlea, oral cavity, pharyngeal constrictor muscles, contralateral parotid and submandibular gland) was obtained with intensity modulated proton therapy vs volumetric modulated arc therapy with statistical significance (p < .05). Ten (27%) patients had a difference in NTCP (photon vs proton plans) greater than 10% for hearing loss and tinnitus: among them, seven qualified for both endpoints, two patients for hearing loss only, and one for tinnitus.<BR><B>UNASSIGNED: </B>In the current study, nearly one-third of patients resulted eligible for proton therapy and they were the most likely to benefit in terms of prevention of hearing loss and tinnitus.